Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and (90)Y-DOTA

Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited the use of PRIT with an anti-CD45 antibody (Ab)-str...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Orozco, Johnnie J., Kenoyer, Aimee L., Lin, Yukang, O’Steen, Shyril, Guel, Rosario, Nartea, Margaret E., Hernandez, Alexandra H., Hylarides, Mark D., Fisher, Darrell R, Balkin, Ethan R., Hamlin, Donald K., Wilbur, D. Scott, Orcutt, Kelly D., Wittrup, K. Dane, Green, Damian J., Gopal, Ajay K., Till, Brian G., Sandmaier, Brenda, Press, Oliver W., Pagel, John M.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718432/
https://ncbi.nlm.nih.gov/pubmed/33082277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0306
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares